Biogen Inc

+3.95 (+1.51%)
: $264.70 -0.47 (-0.18%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)38.89B
Current PE13.13
Forward PE 17.07
2yr Forward PE 16.21
See more stats
Estimates Current Quarter
Revenue$2.36 Billion
Adjusted EPS$3.39
See more estimates
10-Day MA$264.50
50-Day MA$276.95
200-Day MA$252.07
See more pivots

Biogen Inc Stock, NASDAQ:BIIB

225 Binney Street, Cambridge, Massachusetts 02142
United States of America
Phone: +1.617.679.2000
Number of Employees: 8725


Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.